Clinical Study Results, Full-Year Guidance, Upcoming Earnings Schedules, and Trial Completions - Research Report on Covidien,

 Clinical Study Results, Full-Year Guidance, Upcoming Earnings Schedules, and
 Trial Completions - Research Report on Covidien, Mallinckrodt, The Medicines
                         Company, Catalyst, and Akorn

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Covidien
plc, Mallinckrodt plc (NYSE: MNK), The Medicines Company (NASDAQ: MDCO),
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), and Akorn, Inc.
(NASDAQ: AKRX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Covidien plc Research Report 

On October 14, 2013, Covidien plc (Covidien) announced that it has released
positive final results from its DURABILITY II study, and promising preliminary
data from its DEFINITIVE AR trial, both demonstrating the safety and
effectiveness of technologies used in the treatment of peripheral arterial
disease (PAD). Covidien stated that it presented the said results at the
Vascular Interventional Advances (VIVA) 2013 conference, held in Las Vegas,
Nevada. The Company informed that the DURABILITY II three-year results
supported the use of a single long EverFlex self-expanding stent, while the
DEFINITIVE preliminary data showed early success with the combined use of
directional atherectomy and a drug-coated balloon (DAART) in treating lower
limb blockages in PAD patients. The Full Research Report on Covidien plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/a14c_COV]

--

Mallinckrodt plc Research Report 

On October 16, 2013, Mallinckrodt plc (Mallinckrodt) announced financial
guidance for full-year FY 2014 (period ending September 26, 2014). The Company
stated that for full-year FY 2014, it expects annual net sales to be in the
range of $2.15 billion to $2.25 billion on an operational basis, which
excludes impact of foreign exchange fluctuations. The Company informed that it
expects net sales of around $885 million to $930 million for the Global
Medical Imaging segment and net sales of between $1.2 billion to $1.3 billion
for the Specialty Pharmaceuticals segment. The Company added that adjusted
diluted EPS is expected to be in the range of $2.45 to $2.65 for full-year FY
2014. Mark Trudeau, President and CEO of Mallinckrodt said, "Fiscal 2014, our
first full year as an independent public company, will be an important one as
we advance new branded products through the regulatory process and make
strategically important investments in our go-to-market capabilities. Beyond
building our pipeline and marketing capabilities in specialty pharmaceuticals,
we remain committed to becoming more efficient, as demonstrated by the
three-year restructuring program we announced in August 2013." The Full
Research Report on Mallinckrodt plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/24f6_MNK]

--

The Medicines Company Research Report

On October 9, 2013, The Medicines Company announced the completion of two
pharmacodynamics trials that evaluated the transition of its investigational
acute intravenous antiplatelet agent, cangrelor, to chronic oral therapy with
ticagrelor or prasugrel in patients with coronary artery disease (CAD).
According to the Company, the ticagrelor and prasugrel transition studies were
each conducted in 12 CAD patients to test the consistency of inhibition of
platelet aggregation when oral ticagrelor or prasugrel were administered
during or immediately after cangrelor infusion. The Company informed that the
objective of these trials was to demonstrate that patients treated with IV
cangrelor can be directly transitioned to the oral drug without a significant
decrease in the extent of inhibition of platelet aggregation. Simona Skerjanec
PharmD, MBA, Senior Vice President and Innovation Leader for Antiplatelet
Therapies at the Medicines Company said, "Completion of both these studies
evaluating the transition to newer oral agents enables us to add to the wealth
of data that informs cangrelor dosing and administration which is under
regulatory review." The Full Research Report on The Medicines Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5a84_MDCO]

--  

Catalyst Pharmaceutical Partners, Inc. Research Report 

On October 15, 2013, Catalyst Pharmaceutical Partners, Inc. (Catalyst)
announced that the independent Data Monitoring Committee (DMC) overseeing
Catalyst's ongoing pivotal Phase III clinical trial in the US and Europe that
evaluated Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome
(LEMS) has recommended continuation of the trial by Catalyst, as planned,
based on the committee's review of safety and clinical data from the trial.
The Company informed that it has initiated 12 additional sites, in addition to
seven active sites at the time of acquisition, and also expects to initiate
shortly an additional six sites in the US, Europe, Canada, and South America.
Catalyst stated that it expects to complete the enrollment in the trial by the
end of Q4 2013, and to announce top line data from the trial during Q2 2014.
The Full Research Report on Catalyst Pharmaceutical Partners, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/a791_CPRX]

--

Akorn, Inc. Research Report

On October 14, 2013, Akorn, Inc. (Akorn) announced that it will release Q3
2013 earnings before the market opens on Tuesday, November 5, 2013. The
Company informed that it will also host a conference call to discuss its
quarterly results on the same day at 10:00 a.m. ET, which will be followed by
a Q&A session. Akorn stated that a live broadcast of the call will be
available at its website under the Investor Relations section and a replay of
the same will also be available for 30 days after the completion of the call.
The Full Research Report on Akorn, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/900c_AKRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)